Onxeo S.A.: Publication of a New Letter to Shareholders

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specializing
in the development of orphan oncology drugs, today announces the publication of
its new letter to shareholders.

This issue is devoted to our orphan oncology product Beleodaq®. You will find
full information about the product, its key features and indications, as well as
interviews with medical and scientific experts that highlight the broad
potential of this innovative HDAC inhibitor for the treatment of cancer. The
letter also provides feedback about the latest analyst meeting held in Paris in
September and useful details regarding Onxeo’s financial communication.

The shareholder letter is available on our
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51191811&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=03f21b6f0cbc16b23be7dfa9ffc74f76) (Media or
Investors/Shareholders).

About Onxeo

Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key orphan oncology products at the advanced development stage are:
Livatag® (doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (clonidine Lauriad®): Phase II in severe oral mucositis: Positive
final results
Beleodaq® (belinostat): registered in the US in 2nd line treatment of peripheral
T-cell lymphoma
For more information, visit the
website www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3
A 
%2F%2Fwww.onxeo.com&esheet=51191811&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=2&md5=4c808b87ea0cd95e6c404b3aa32a39d9)

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51191811&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=3&md5=5937ddff7
4 
5c3039648cd32761084d11)

Follow us on twitter @Onxeo_

Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51191811&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=4&md5=d7ccdfb8ff4351a398102586567336a3)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51191811&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=5&md5=99d39916c80c42c94c0f17fe5c924c72)).
Contacts

Onxeo S.A.
Judith Greciet, CEO
j.greciet@onxeo.com
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Caroline Carmagnol and Florence Portejoie
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 6 47 38 90 04